Abstract
A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.
| Original language | English |
|---|---|
| Pages (from-to) | 217-222 |
| Number of pages | 6 |
| Journal | Drug Development Research |
| Volume | 14 |
| Issue number | 3-4 |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Organic Chemistry
- Drug Discovery
- Pharmacology
Cite this
A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery. / Mangoni, A.; Perin, C.; Smirne, S.; Piccolo, I.; De Filippi, F.; Marchetti, C.; Motta, A.; Monza, G. C.
In: Drug Development Research, Vol. 14, No. 3-4, 1988, p. 217-222.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A double-blind, placebo-controlled study with oxiracetam in demented patients administered the Luria-Nebraska Neuropsychological Battery
AU - Mangoni, A.
AU - Perin, C.
AU - Smirne, S.
AU - Piccolo, I.
AU - De Filippi, F.
AU - Marchetti, C.
AU - Motta, A.
AU - Monza, G. C.
PY - 1988
Y1 - 1988
N2 - A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.
AB - A formal multicenter, double-blind, between-patient trial was carried out to evaluate the efficacy and tolerability of oxiracetam (OXIR) (800-mg tablets), in comparison with placebo, each given twice daily for 24 weeks to patients suffering from probable or possible Alzheimer's disease (AD). Efficacy was assessed by the Inventory of Psychic and Somatic Complaints in the Elderly (IPSC-E), administered at entry and after 8, 16, and 24 weeks of treatment, and by the Luria-Nebraska Neuropsychological Battery (LNNB), administered at the beginning and at the end of the study. Thirty patients (16 on OXIR and 14 on placebo), 20 males and 10 females, mean age 62 years (range 52-79), were enrolled and completed the study. A significant (P <0.01) difference between treatments in the total score of the IPSC-E, as well as in some LNNB scales, was observed. In particular, patients on OXIR showed an improvement over time, while the condition of patients on placebo remained unchanged or tended to get worse. No difference in tolerability between the active drug and placebo was observed.
UR - http://www.scopus.com/inward/record.url?scp=0024152789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024152789&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0024152789
VL - 14
SP - 217
EP - 222
JO - Drug Development Research
JF - Drug Development Research
SN - 0272-4391
IS - 3-4
ER -